ARC Centre of Excellence in Synthetic Biology

Synthetic Biology

News

22, Nov 2023

Centre of Excellence researchers awarded at Synthetic Biology Australasia Conference 2023

Centre of Excellence researchers from Kirill Alexandrov’s Research Group at QUT, Dr Elena Eremeeva, Mica Fiorito have each picked up awards for the best talks, and Roxane Mutschler has won a poster award at the Synthetic Biology Australasia Conference (SBA23), which took place in Perth at The University of Western Australia on 15-17 November 2023.

Best talks awards

Synergistic Sensing: Harnessing the Power of Protein-Nucleic Acid Hybrid Biosensors

Dr Elena Eremeeva and her team’s research unveils a novel approach to constructing synthetic biosensors, combining protein and nucleic acid recognition capabilities. Bridging the gap between nature and technology, these hybrid devices promise enhanced detection for various biomolecules, from drugs to disease biomarkers.

Protein biosensors for personalised monitoring

In their study, Mica and her team address the challenges in monitoring the anti-epileptic drug phenytoin, which has a narrow reference range and high reported adverse reactions. They propose the use of protein biosensors as a revolutionary approach to overcome the limitations of current methods. Protein biosensors have the potential to provide rapid, low-cost, and personalised monitoring.

Poster presentation award

Artificial allosteric protein biosensors for use in point-of-care diagnostic systems

Roxane and her team aim to identify and measure salivary-based biomarkers for the early detection of heart failure, using an engineered enzymatic based point-of-care biosensor.

Early diagnosis, risk management and monitoring treatment in patients with heart failure is an unmet clinical need. Heart failure has a 50 percent mortality rate within five years of diagnosis and currently 25 percent of heart failure patients below 65 years of age are re-hospitalised within 30 days of being discharged. Adequate accessibility to decentralised testing methods such as the use of point-of-care diagnostics are key to accurately identifying heart failure patients’ risks after being discharged from hospital.